Equashield to Open New $30 Million Manufacturing Facility to Accommodate Future Growth in Product Portfolio and Increase Production Capabilities
PORT WASHINGTON, New York, May 23, 2017 /PRNewswire/ —
Equashield, a leading provider of Closed System Transfer Devices (CSTDs) for the safe and simple handling of hazardous drugs, today held a groundbreaking for a new manufacturing plant. The company will invest an estimated $30 million to build the new plant to meet the growing market demand for manual and automated hazardous drug compounding devices.
The new manufacturing facility will be built on a 3 Acre Plot with an option to expand by another 1.5 Acres. The new plant will expand the manufacturing capabilities of EQUASHIELD, Equashield’s flagship CSTD, as well as the new Equashield Pro closed system drug compounding robot, first unveiled at the ASHP Midyear meeting.
“As Equashield continues to expand into new international markets, this plant will provide the capacity to significantly expand our product portfolio, while enabling us to fulfill worldwide need for current and future CSTD demand,” said Marino Kriheli, Co-founder of Equashield. “With these enhanced capabilities Equashield can continue to make a difference for those who work with and around hazardous drugs.”
Construction of the 112,000-square foot building is expected to complete in July 2019. It will include a 20,000-square foot cleanroom space, incorporating the HVAC variable refrigerant flow (VRF) system for cooling and air conditioning. Production will be fully automated, from raw materials entry to packaging and palletizing, to preserve sterility of products.
Equashield is a leading provider of a full range of manual and automated solutions to hospitals for the compounding and administration of hazardous drugs. Equashield’s product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD® Pro, the first ever closed system drug compounding robot. Equashield’s CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure. The globally awarded EQUASHIELD® II covers more routes of exposure than alternative systems by preventing contamination of syringe plungers and drug residuals on connector surfaces, as well as exposure to drug vapors. Studies have shown Equashield’s CSTD to be faster to deploy and easier to use than competing systems, and the system has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. EQUASHIELD is in use by hundreds of hospitals and clinics around the world, and has been both cleared by the FDA under the ONB product code, and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days.
For more information: http://www.equashield.com